The analysis showed that the expression of PLEKHA4 was upregulated in central nervous system neoplasms, breast cancer, head and neck cancer, and melanoma and downregulated in bladder cancer and ovarian cancer (Figure 1(a)). This evidence concerns the gene PLEKHA4 and breast carcinoma.